Gavetro: Genetech, Inc.

 Gavetro

Company Name: Genetech, Inc. 

Date of Approval: September 4, 2020

Therapeutic Use: Non-small Cell Lung Cancer. 

Gavetro is an oral selective RET inhibitor for the treatment of adult patient with metastatic rearranged during transfection fusion positive non-small cell lung cancer as detected by FDA approved test.